Celltrion Inc (068270):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Celltrion Inc (068270) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9825
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis and psoriasis. Its pipeline portfolio spans monoclonal antibody biosmilars for the treatment of rheumatoid arthritis; colorectal cancer; large Intestine Cancer and respiratory disease; and antibody biologics for and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, seasonal influenza antibody; and antibody drug conjugates. Celltrion develops drugs by utilizing its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon city, South Korea.

Celltrion Inc (068270) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Licensing Agreements 16
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Equity Offering 19
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Debt Offering 20
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Acquisition 25
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc – Key Competitors 28
Celltrion Inc – Key Employees 29
Celltrion Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Legal and Regulatory 31
Sep 18, 2018: Celltrion receives EIR from the FDA 31
Product News 32
05/23/2017: Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra 32
05/18/2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) 33
02/22/2017: Mundipharma to launch Truxima (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in seven European markets 34
02/17/2017: New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE 35
02/17/2017: Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohns Disease 36
Product Approvals 37
May 30, 2018: Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review 37
Apr 06, 2018: Celltrion Receives CRL from the U.S. FDA for rituximab biosimilar 38
Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab) 39
Clinical Trials 40
Dec 11, 2017: Top UK university hospital unveils data that support the use of rapid infusion for Truxima (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma 40
Nov 05, 2017: Celltrion Healthcare Presents Phase III Switching Data Supporting the Long-Term Efficacy and Safety of Truxima (CT-P10, Biosimilar Rituximab) in Rheumatoid Arthritis Patients 41
Oct 29, 2017: One Year Maintenance And Switching Data In Patients With Crohn’s Disease Support The Use Of Inflectra (Infliximab CT-P13) In IBD 42
Jun 14, 2017: Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis 43
May 12, 2017: Celltrion Healthcare: Lancet Publishes Full Data-Set from Influential NOR-SWITCH Study 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Celltrion Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc, Key Competitors 28
Celltrion Inc, Key Employees 29
Celltrion Inc, Subsidiaries 30

List of Figures
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Celltrion Inc (068270):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Targa Resources Partners LP (NGLS PR A):企業の財務・戦略的SWOT分析
    Targa Resources Partners LP (NGLS PR A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Clark Public Utilities:企業の戦略的SWOT分析
    Clark Public Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Presence Health:企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • NEC Networks & System Integration Corp (1973):企業の財務・戦略的SWOT分析
    NEC Networks & System Integration Corp (1973) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • BPH Energy Ltd (BPH):企業の財務・戦略的SWOT分析
    BPH Energy Ltd (BPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Rafael Advanced Defense Systems Ltd:企業の戦略・SWOT・財務情報
    Rafael Advanced Defense Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Rafael Advanced Defense Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Enerplus Corp (ERF):石油・ガス:M&Aディール及び事業提携情報
    Summary Enerplus Corp (Enerplus), formerly Enerplus Resources Fund is an oil and gas company that offers exploration and development services. The company provides exploration and development of natural resource properties for the production of crude oil, light and heavy oil, natural gas, shallow ga …
  • SandRidge Energy Inc (SD):企業の財務・戦略的SWOT分析
    SandRidge Energy Inc (SD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Lorain-Medina Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Lorain-Medina Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • DLF Limited:企業の戦略・SWOT・財務情報
    DLF Limited - Strategy, SWOT and Corporate Finance Report Summary DLF Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Arena Pharmaceuticals Inc (ARNA)-製薬・医療分野:企業M&A・提携分析
    Summary Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. Its pipeline portfolio encompasses etrasimod for multiple inflammatory indications; ralinepag for the treatment of pulmonary arterial …
  • Hospira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Hospira Inc (Hospira), a subsidiary of Pfizer Inc, is a medical device company that offers injectable drugs and infusion technologies. The company offers products such as generic acute-care and oncology injectables, biosimilars, infusion systems, IV sets, IV safety devices, biosimilars, diff …
  • HepQuant Llc:企業の製品パイプライン分析2018
    Summary Hepquant LLC (Hepquant) is a medical device company that offers diagnostic products. The company develops and markets patented and patent-pending technology for assessing liver function of patients with chronic liver disease. It offers investigational combination drug and diagnostic devices. …
  • Bloomberg L.P.:戦略・SWOT・企業財務分析
    Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report Summary Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sarku Japan:企業の戦略・SWOT・財務情報
    Sarku Japan - Strategy, SWOT and Corporate Finance Report Summary Sarku Japan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Impact Developer & Contractor SA:企業の戦略・SWOT・財務情報
    Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report Summary Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • City of Hope:企業のM&A・事業提携・投資動向
    City of Hope - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's City of Hope Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • PepsiCo Inc:戦略・SWOT・企業財務分析
    PepsiCo Inc - Strategy, SWOT and Corporate Finance Report Summary PepsiCo Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Verrica Pharmaceuticals Inc (VRCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Verrica Pharmaceuticals Inc (Verrica) is a clinical-stage medical dermatology company that discovers, develops and commercializes therapeutics for the treatment of skin diseases. The company’s lead product candidate, VP-102, is in two phase 3 clinical trials for the treatment of molluscum co …
  • Torii Pharmaceutical Co Ltd (4551)-製薬・医療分野:企業M&A・提携分析
    Summary Torii Pharmaceutical Co Ltd (Torii) a subsidiary of Japan Tobacco Inc is a healthcare product provider that manufactures and markets products such as antebate ointment, antebate cream and urinorm used for the treatment of hyperuricemia and gout. The company offers products for the treatment …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆